GSK Valtrex Cold Sore Promotions Will Focus On One-Day, Oral Treatment
Executive Summary
GlaxoSmithKline's Valtrex herpes labialis promotions will focus on the drug's convenience as an oral, one-day therapy following FDA's supplemental approval of the antiviral
You may also be interested in...
Roche Kytril Acquisition From SmithKline Strengthens Hospital Focus In U.S.
Roche's acquisition of the anti-emetic Kytril from SmithKline Beecham will build on Roche's strength in the U.S. hospital market.
Denavir OTC Switch Falters On Viral Resistance Questions
Two FDA advisory committees unanimously disagreed on whether to recommend approval of the Rx-to-OTC switch of SmithKline Beecham's Denavir 1% penciclovir cream for cold sores on Dec. 1.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011